Antineoplastic
WikiDoc Resources for Antineoplastic |
Articles |
---|
Most recent articles on Antineoplastic Most cited articles on Antineoplastic |
Media |
Powerpoint slides on Antineoplastic |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Antineoplastic at Clinical Trials.gov Trial results on Antineoplastic Clinical Trials on Antineoplastic at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Antineoplastic NICE Guidance on Antineoplastic
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Antineoplastic Discussion groups on Antineoplastic Patient Handouts on Antineoplastic Directions to Hospitals Treating Antineoplastic Risk calculators and risk factors for Antineoplastic
|
Healthcare Provider Resources |
Causes & Risk Factors for Antineoplastic |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Antineoplastics (or "antitumor antibiotics", or "noncovalent DNA-binding drugs", or "cytotoxic antibiotics", see also neoplastics) are drugs that inhibit and combat the development of tumors.
In the Anatomical Therapeutic Chemical Classification System, they are classified under L01D.
Health Effects/Occupational Exposure
The adverse health effects associated with antineoplastic agents (cancer chemotherapy drugs, cytotoxic drugs) in cancer patients and some non-cancer patients treated with these drugs are well documented. The very nature of antineoplastic agents make them harmful to healthy cells and tissues as well as the cancerous cells. For cancer patients with a life-threatening disease, there is certainly a great benefit to treatment with these agents. However, for the health care workers who are exposed to antineoplastic agents as part of their work practice, precautions should be taken to eliminate or reduce exposure as much as possible. Pharmacists who prepare these drugs or nurses who may prepare and/or administer them are the two occupational groups who have the highest potential exposure to antineoplastic agents. Additionally, physicians and operating room personnel may also be exposed through the treatment of patients. Hospital staff, such as shipping and receiving personnel, custodial workers, laundry workers and waste handlers, all have potential exposure to these drugs during the course of their work. The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs.[1]
Modes of action
Antineoplastics work by:
- Inhibiting topoisomerase II, thereby stopping DNA from being unwound, which is required for both DNA replication and RNA/protein synthesis.
- Generating free radicals.
They are products of various strains of the soil fungus Streptomyces.
Examples
- actinomycin (L01DA01 (WHO)).
- The most important immunosuppressant from this group is dactinomycin, which is used to in kidney transplantations.
- anthracyclines
- doxorubicin (L01DB01 (WHO))
- daunorubicin (L01DB02 (WHO))
- epirubicin (L01DB03 (WHO)), which also inhibit topoisomerase II)
- other cytotoxic antibiotics